AANP PMHNP Certification Exam 2026 |
Complete Practice Questions, Verified
Answers & Detailed Rationales | Psychiatric
Mental Health NP Study Guide
AANP PMHNP CERTIFICATION EXAM 2026 | COMPLETE PRACTICE QUESTIONS
DOCUMENT OVERVIEW
• 200 Verified Practice Questions with clinically accurate answers and
comprehensive rationales designed to mirror actual AANP PMHNP certification
exam format and difficulty level
• Complete Topic Coverage spanning psychopharmacology, psychiatric
assessment, therapeutic modalities, all major psychiatric disorders, neurobiology,
and professional standards to ensure thorough exam preparation
HOW TO USE THIS STUDY MATERIAL
Read each question carefully. Attempt to answer before reviewing the correct
answer and rationale. Use the detailed rationales to deepen your understanding of
concepts and strengthen knowledge gaps. Work through questions systematically
by topic to build comprehensive mastery across all PMHNP exam domains.
SECTION 1: PSYCHOPHARMACOLOGY & PSYCHOTROPIC MEDICATIONS
QUESTION 1:
A patient with major depressive disorder is started on sertraline 50 mg daily.
After 2 weeks, the patient reports no improvement in mood. What is the most
appropriate next step?
A) Switch to a different SSRI
B) Increase sertraline to 100 mg daily
,C) Add an atypical antipsychotic
D) Discontinue sertraline
E) Refer for electroconvulsive therapy
CORRECT ANSWER: B) Increase sertraline to 100 mg daily
RATIONALE: SSRIs typically require 4-6 weeks at therapeutic dosage to
demonstrate full efficacy. Two weeks is insufficient time to evaluate treatment
response. Standard practice involves increasing the dose at 2-4 week intervals if
therapeutic effect is not observed. Doses can be titrated up to therapeutic ranges
(sertraline typically 50-200 mg daily) before considering alternative treatments.
Switching medications or adding augmentation strategies is premature at this
stage.
QUESTION 2:
Which of the following antidepressants is most likely to cause weight gain?
A) Bupropion
B) Fluoxetine
C) Mirtazapine
D) Sertraline
E) Paroxetine
CORRECT ANSWER: C) Mirtazapine
RATIONALE: Mirtazapine is a noradrenergic and specific serotonergic
antidepressant (NaSSA) known for significant weight gain, often 2-3 kg within the
first month. This occurs due to increased appetite from H1-receptor antagonism.
Bupropion is weight-neutral to weight-reducing. Fluoxetine and sertraline are
generally weight-neutral. Paroxetine has moderate weight gain potential but less
than mirtazapine. Understanding these metabolic effects is crucial for medication
selection based on patient factors.
,QUESTION 3:
A 34-year-old male with bipolar I disorder is prescribed lithium carbonate.
What is the therapeutic serum level range for maintenance treatment?
A) 0.2-0.4 mEq/L
B) 0.6-1.2 mEq/L
C) 1.5-2.5 mEq/L
D) 2.5-3.5 mEq/L
E) 3.5-4.5 mEq/L
CORRECT ANSWER: B) 0.6-1.2 mEq/L
RATIONALE: Lithium therapeutic levels for maintenance are 0.6-1.2 mEq/L. Acute
mania typically requires 1.0-1.5 mEq/L. Toxicity increases significantly above 1.5
mEq/L. Levels below 0.6 mEq/L are subtherapeutic for most patients. Regular
monitoring of lithium levels is essential given the narrow therapeutic window and
risk of toxicity affecting renal and thyroid function. Baseline kidney function and
thyroid studies must be obtained before initiating lithium.
QUESTION 4:
Which SSRI is most likely to cause hyponatremia (SIADH)?
A) Citalopram
B) Fluoxetine
C) Sertraline
D) Paroxetine
E) Escitalopram
CORRECT ANSWER: D) Paroxetine
RATIONALE: Paroxetine has the highest association with SSRI-induced
hyponatremia/SIADH among commonly used SSRIs. Risk is elevated in elderly
, patients and early treatment phases. Fluoxetine has the longest half-life and lowest
SIADH risk. Citalopram, sertraline, and escitalopram have lower rates. All SSRIs
carry SIADH risk, particularly in the first 2 weeks. Sodium monitoring is essential,
especially in elderly patients or those on concurrent medications affecting sodium.
QUESTION 5:
A 45-year-old woman is taking fluoxetine for depression. She begins taking
tramadol for chronic pain. What serious adverse effect should the PMHNP
anticipate?
A) Serotonin syndrome
B) Neuroleptic malignant syndrome
C) Anticholinergic toxicity
D) Withdrawal syndrome
E) Hypertensive crisis
CORRECT ANSWER: A) Serotonin syndrome
RATIONALE: Concurrent use of SSRIs (fluoxetine) and tramadol significantly
increases serotonin syndrome risk. Tramadol inhibits serotonin and
norepinephrine reuptake and enhances serotonin release. Classic serotonin
syndrome presents with agitation, confusion, tremors, rigidity, hyperthermia, and
autonomic instability. This is a potentially life-threatening condition requiring
immediate discontinuation of serotonergic agents. Patients must be counseled
about this serious interaction. Alternative analgesics should be considered.
QUESTION 6:
Which atypical antipsychotic has the lowest metabolic risk profile?
A) Olanzapine
B) Aripiprazole
Complete Practice Questions, Verified
Answers & Detailed Rationales | Psychiatric
Mental Health NP Study Guide
AANP PMHNP CERTIFICATION EXAM 2026 | COMPLETE PRACTICE QUESTIONS
DOCUMENT OVERVIEW
• 200 Verified Practice Questions with clinically accurate answers and
comprehensive rationales designed to mirror actual AANP PMHNP certification
exam format and difficulty level
• Complete Topic Coverage spanning psychopharmacology, psychiatric
assessment, therapeutic modalities, all major psychiatric disorders, neurobiology,
and professional standards to ensure thorough exam preparation
HOW TO USE THIS STUDY MATERIAL
Read each question carefully. Attempt to answer before reviewing the correct
answer and rationale. Use the detailed rationales to deepen your understanding of
concepts and strengthen knowledge gaps. Work through questions systematically
by topic to build comprehensive mastery across all PMHNP exam domains.
SECTION 1: PSYCHOPHARMACOLOGY & PSYCHOTROPIC MEDICATIONS
QUESTION 1:
A patient with major depressive disorder is started on sertraline 50 mg daily.
After 2 weeks, the patient reports no improvement in mood. What is the most
appropriate next step?
A) Switch to a different SSRI
B) Increase sertraline to 100 mg daily
,C) Add an atypical antipsychotic
D) Discontinue sertraline
E) Refer for electroconvulsive therapy
CORRECT ANSWER: B) Increase sertraline to 100 mg daily
RATIONALE: SSRIs typically require 4-6 weeks at therapeutic dosage to
demonstrate full efficacy. Two weeks is insufficient time to evaluate treatment
response. Standard practice involves increasing the dose at 2-4 week intervals if
therapeutic effect is not observed. Doses can be titrated up to therapeutic ranges
(sertraline typically 50-200 mg daily) before considering alternative treatments.
Switching medications or adding augmentation strategies is premature at this
stage.
QUESTION 2:
Which of the following antidepressants is most likely to cause weight gain?
A) Bupropion
B) Fluoxetine
C) Mirtazapine
D) Sertraline
E) Paroxetine
CORRECT ANSWER: C) Mirtazapine
RATIONALE: Mirtazapine is a noradrenergic and specific serotonergic
antidepressant (NaSSA) known for significant weight gain, often 2-3 kg within the
first month. This occurs due to increased appetite from H1-receptor antagonism.
Bupropion is weight-neutral to weight-reducing. Fluoxetine and sertraline are
generally weight-neutral. Paroxetine has moderate weight gain potential but less
than mirtazapine. Understanding these metabolic effects is crucial for medication
selection based on patient factors.
,QUESTION 3:
A 34-year-old male with bipolar I disorder is prescribed lithium carbonate.
What is the therapeutic serum level range for maintenance treatment?
A) 0.2-0.4 mEq/L
B) 0.6-1.2 mEq/L
C) 1.5-2.5 mEq/L
D) 2.5-3.5 mEq/L
E) 3.5-4.5 mEq/L
CORRECT ANSWER: B) 0.6-1.2 mEq/L
RATIONALE: Lithium therapeutic levels for maintenance are 0.6-1.2 mEq/L. Acute
mania typically requires 1.0-1.5 mEq/L. Toxicity increases significantly above 1.5
mEq/L. Levels below 0.6 mEq/L are subtherapeutic for most patients. Regular
monitoring of lithium levels is essential given the narrow therapeutic window and
risk of toxicity affecting renal and thyroid function. Baseline kidney function and
thyroid studies must be obtained before initiating lithium.
QUESTION 4:
Which SSRI is most likely to cause hyponatremia (SIADH)?
A) Citalopram
B) Fluoxetine
C) Sertraline
D) Paroxetine
E) Escitalopram
CORRECT ANSWER: D) Paroxetine
RATIONALE: Paroxetine has the highest association with SSRI-induced
hyponatremia/SIADH among commonly used SSRIs. Risk is elevated in elderly
, patients and early treatment phases. Fluoxetine has the longest half-life and lowest
SIADH risk. Citalopram, sertraline, and escitalopram have lower rates. All SSRIs
carry SIADH risk, particularly in the first 2 weeks. Sodium monitoring is essential,
especially in elderly patients or those on concurrent medications affecting sodium.
QUESTION 5:
A 45-year-old woman is taking fluoxetine for depression. She begins taking
tramadol for chronic pain. What serious adverse effect should the PMHNP
anticipate?
A) Serotonin syndrome
B) Neuroleptic malignant syndrome
C) Anticholinergic toxicity
D) Withdrawal syndrome
E) Hypertensive crisis
CORRECT ANSWER: A) Serotonin syndrome
RATIONALE: Concurrent use of SSRIs (fluoxetine) and tramadol significantly
increases serotonin syndrome risk. Tramadol inhibits serotonin and
norepinephrine reuptake and enhances serotonin release. Classic serotonin
syndrome presents with agitation, confusion, tremors, rigidity, hyperthermia, and
autonomic instability. This is a potentially life-threatening condition requiring
immediate discontinuation of serotonergic agents. Patients must be counseled
about this serious interaction. Alternative analgesics should be considered.
QUESTION 6:
Which atypical antipsychotic has the lowest metabolic risk profile?
A) Olanzapine
B) Aripiprazole
